Healthcare Industry News:  stem cell therapeutics 

Regenerative Medicine

 News Release - April 3, 2007

NeoStem Announces Launch of Government Affairs Initiative

Company's Next Generation Health Services Could Provide Proven Therapeutics for Thousands of Exposed First Responders Nationwide

NEW YORK--(HSMN NewsFeed)--NeoStem, Inc. (OTCBB:NEOI ), the first company to specialize in the collection, processing and storage of stem cells from healthy adult donors for personal use in times of critical medical need, announced today the launch of a "Government Affairs" initiative to lobby key members of the federal government on the growing threat to the thousands of first responders from radiation exposure following a possible nuclear assault.

NeoStem's "Government Affairs" initiative is a concerted effort to leverage the Company's next generation services to allow the thousands of first responders, including firemen, police officers and National Guardsmen, across the nation to store their own, genetically-matched adult stem cells to treat bone marrow failure caused by nuclear radiation, a common cause of death following exposure. The use of adult stem cells to treat diseased bone marrow has been a proven therapy for more than 40 years.

"We have an obligation to provide every possible advantage to the thousands of brave men and women who are at the greatest risk of radiation exposure," said Arlene Graime, NeoStem's Director of Government Affairs and Special Projects. "NeoStem is fully committed to lobbying key members of the state and federal government to give first responders the advantage of collecting and storing their own stem cells for personal therapeutic use."

Ms. Graime was recently hired by NeoStem to spearhead initiatives with the Department of Defense and key Congressional committees to raise visibility for NeoStem's proprietary adult stem cell collection, processing and storage technology.

Additionally, NeoStem named Dr. Neil C. Livingstone, a noted expert on national security, to the Company's Advisory Board. Dr. Livingstone has served on advisory panels to The Secretary of State, The Chief of Naval Operations, and The Pentagon. He has testified before Congress and delivered more than 500 major addresses in the U.S. and abroad, including recent speeches at The House of Commons and The United Nations.

"NeoStem is fully committed to exploiting our next generation biotech services to both assist on national security issues and to continually build shareholder value," said Robin Smith, M.D., Chief Executive Officer of NeoStem. "We believe that this concerted effort to access key government officials will significantly accelerate that mission."

NeoStem is developing a nationwide health-industry network to capitalize on the predicted $8.5 billion stem cell therapeutics industry. NeoStem's visionary senior management, non-capital intensive business model and proprietary processes are making an immediate impact in what many believe to be the "next big thing in consumer health marketing." The Company has termed this paradigm shift in the medical industry as "bio-insurance," which empowers health-conscious adults to extract their own (autologous) stem cells to ensure prompt access for therapeutic use in times of critical medical need.

About NeoStem, Inc.

NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Independent market researchers estimate that stem cell therapy sales in the United States are projected to reach more than $700 million by 2010 and $8.5 billion by 2016 based on therapies under development. Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the fast-growing national trend toward personal "bio-insurance."

The Company's non-capital intensive business plan is a service model that is completely scalable and can be quickly implemented, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.

For more information, please visit: For investor-specific information and resources, visit To view current stock quotes and news, visit To view an investor fact sheet about the company, visit

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; and (vi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit

Source: NeoStem

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.